Regulation of Nitric Oxide Bioavailability in Chronic Obstructive Pulmonary Disease: A Mechanistic Approach

NCT01398943 NA COMPLETED Results posted

More patients with chronic obstructive pulmonary disease (COPD) die from cardiovascular disease than direct pulmonary complications. Inflammation and oxidative stress, characteristic in COPD, are likely contributors to the reduction in nitric oxide (NO) bioavailability and vascular endothelial dysfunction in COPD patients; however, this has yet to be determined. Thus, the overall objective of this proposal is to identify the role of NO bioavailability in contributing to vascular endothelial dysfunction in patients with COPD and to provide insight into the molecular mechanisms involved. Our central hypothesis is that inflammation and oxidative stress, both independently, contribute to the reduction in NO bioavailability and vascular endothelial dysfunction in patients with COPD.

Details

Lead sponsor	Augusta University
Phase	NA
Status	COMPLETED
Enrolment	60
Start date	2010-09
Completion	2015-06

Conditions

• Pulmonary Disease, Chronic Obstructive

Interventions

• Tetrahydrobiopterin (BH4)
• Antioxidant Cocktail

Primary outcomes

• Flow-Mediated Dilation (FMD) — Post FMD was taken approximately 110 min after baseline
  Brachial artery FMD induced by reactive hyperemia will be used to assess vascular endothelial function at baseline and several hours after each experimental intervention.

Countries

United States